Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odetiglucan + immune checkpoint inhibitor
- Development stage
- Unknown
- Lead developer
- HiberCell
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Imprime PGG (odetiglucan) is a soluble yeast-derived β-1,3/1,6-glucan that acts as an innate immune activator. It functions as a pathogen-associated molecular pattern (PAMP) that binds to the Dectin-1 receptor on innate immune cells, such as neutrophils and monocytes. This binding triggers a cascade that reprograms the immunosuppressive tumor microenvironment, enhances antigen presentation, and promotes T cell activation. When used in combination with immune checkpoint inhibitors (ICIs), such as pembrolizumab, Imprime PGG is intended to synergistically enhance the anti-tumor immune response. The combination has been investigated in Phase 2 clinical trials for various solid tumors, including metastatic breast cancer and advanced melanoma, by HiberCell (which acquired the program from Biothera Pharmaceuticals).
- Other names
- Imprime PGG + ICIodetiglucan + ICIBTH1677 + ICI
02
Targets
FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)αMβ2 (Integrin αMβ2)PDCD1 (Programmed cell death protein 1 receptor)CLEC7A (Dectin-1)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on odetiglucan + immune checkpoint inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odetiglucan + immune checkpoint inhibitor.